DK1313716T3 - Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister - Google Patents

Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister

Info

Publication number
DK1313716T3
DK1313716T3 DK01963733T DK01963733T DK1313716T3 DK 1313716 T3 DK1313716 T3 DK 1313716T3 DK 01963733 T DK01963733 T DK 01963733T DK 01963733 T DK01963733 T DK 01963733T DK 1313716 T3 DK1313716 T3 DK 1313716T3
Authority
DK
Denmark
Prior art keywords
alkyl
unsubstituted
oxazolyl
substituted
acid derivatives
Prior art date
Application number
DK01963733T
Other languages
Danish (da)
English (en)
Inventor
Sarah Beth Jones
Leonard Larry Junio Winneroski
Alexander Glenn Godfrey
Yanping Xu
Dawn Alisa Brooks
James Ray Mccarthy
Christopher John Rito
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1313716T3 publication Critical patent/DK1313716T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01963733T 2000-08-23 2001-08-23 Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister DK1313716T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (1)

Publication Number Publication Date
DK1313716T3 true DK1313716T3 (da) 2007-08-27

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01963733T DK1313716T3 (da) 2000-08-23 2001-08-23 Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister

Country Status (26)

Country Link
US (2) US6930120B2 (ko)
EP (1) EP1313716B1 (ko)
JP (1) JP2004506721A (ko)
KR (1) KR20030027054A (ko)
CN (1) CN1471517A (ko)
AT (1) ATE361283T1 (ko)
AU (1) AU2001284659A1 (ko)
BR (1) BR0113409A (ko)
CA (1) CA2418104A1 (ko)
CY (1) CY1107679T1 (ko)
CZ (1) CZ2003482A3 (ko)
DE (1) DE60128239T2 (ko)
DK (1) DK1313716T3 (ko)
EA (1) EA200300286A1 (ko)
EC (1) ECSP034504A (ko)
ES (1) ES2286137T3 (ko)
HU (1) HUP0300857A3 (ko)
IL (1) IL154110A0 (ko)
MX (1) MXPA03001558A (ko)
NO (1) NO20030729L (ko)
NZ (1) NZ523804A (ko)
PL (1) PL360744A1 (ko)
PT (1) PT1313716E (ko)
SK (1) SK1872003A3 (ko)
WO (1) WO2002016331A1 (ko)
ZA (1) ZA200300570B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
AU2001284660A1 (en) * 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
KR100654516B1 (ko) * 2001-05-15 2006-12-05 에프. 호프만-라 로슈 아게 당뇨병 치료에서 ppar-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
WO2004005266A1 (en) 2002-07-03 2004-01-15 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
CA2495942C (en) * 2002-08-30 2010-03-23 F. Hoffmann-La Roche Ag Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
MXPA05002704A (es) 2002-09-12 2005-05-05 Hoffmann La Roche Compuestos de acido n-sustituido-1h-indol-5-propionico como agonistas de los receptores activados proliferadores de peroxisomas (ppar) utiles para el tratamiento de diabetes.
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
KR100699614B1 (ko) * 2002-11-08 2007-03-23 에프. 호프만-라 로슈 아게 퍼옥시좀 증식자 활성화된 수용체 작용제로서의 치환된4-알콕시옥사졸 유도체
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MXPA06001916A (es) * 2003-08-20 2006-05-17 Lilly Co Eli Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
DE602004004156T2 (de) * 2003-08-20 2007-10-11 Eli Lilly And Co., Indianapolis Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
WO1999046232A1 (fr) 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
JP2003508389A (ja) 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ(チア)ゾール誘導体およびそのpparモジュレーターとしての使用
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
AU2001284660A1 (en) 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
NO20030729L (no) 2003-04-02
ZA200300570B (en) 2004-04-21
PT1313716E (pt) 2007-07-11
US6930120B2 (en) 2005-08-16
HUP0300857A2 (hu) 2003-10-28
HUP0300857A3 (en) 2007-03-28
KR20030027054A (ko) 2003-04-03
US20040097590A1 (en) 2004-05-20
SK1872003A3 (en) 2003-07-01
IL154110A0 (en) 2003-07-31
MXPA03001558A (es) 2003-06-06
PL360744A1 (en) 2004-09-20
CN1471517A (zh) 2004-01-28
BR0113409A (pt) 2003-07-01
AU2001284659A1 (en) 2002-03-04
DE60128239T2 (de) 2008-01-10
EA200300286A1 (ru) 2003-08-28
JP2004506721A (ja) 2004-03-04
NO20030729D0 (no) 2003-02-14
CZ2003482A3 (cs) 2003-05-14
ES2286137T3 (es) 2007-12-01
ATE361283T1 (de) 2007-05-15
CY1107679T1 (el) 2013-04-18
NZ523804A (en) 2004-09-24
EP1313716A1 (en) 2003-05-28
WO2002016331A1 (en) 2002-02-28
CA2418104A1 (en) 2002-02-28
EP1313716B1 (en) 2007-05-02
ECSP034504A (es) 2003-04-25
DE60128239D1 (de) 2007-06-14
US7345070B2 (en) 2008-03-18
US20050245584A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
DK1313716T3 (da) Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
AU2001284658A1 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
EP1357115A4 (en) ALKANOIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
SE423812B (sv) Forfarande for framstellning av terapeutiskt aktiva derivat av azetidin-2-karboxylsyra, prolin och pipekolinsyra
PT96255A (pt) Processo para a preparacao de novos derivados da 1-naftil-piperazina
DK0540051T3 (da) Aromatiske amidinderivater og salte deraf
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
AR037898A1 (es) Compuesto de benzamida, uso de un compuesto de benzamida en la fabricacion de un medicamento, proceso para su preparacion y composicion farmaceutica que lo comprende
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
WO2002038553A3 (en) Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
NO991957D0 (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske sammensetninger inneholdende dem
EP1394154A4 (en) HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID
KR900001684A (ko) (1-히드록시-2- 피페리딜알킬)-인돌-2-온, 2-퀴놀리논, 2- 벤조[b] 아자피논, 벤즈이미다졸-2-온 및 퀴나졸린-2-온의 유도체, 그의 제조 및 치료요법에서의 그의 적용
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
WO2002028844A1 (fr) Dérivés thiazole ou oxazole
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
DK0508740T3 (da) Thiazolidindionderivater, deres fremstilling og anvendelse.
SE8006365L (sv) Cyklohexankarboxylsyraderivat
NO994340L (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
NO994209L (no) Fremgangsmaate for fremstilling av 2-ÄÄ(2-pyridinyl)metylÜsulfinylÜ-1H-benzimidazoler og nye forbindelser til anvendelse for dette formaal
DK1559714T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-aminothiophenderivater og 3-aminothiophenderivater
DK1023898T3 (da) Cyanoindoler som serotonin-genoptagningsinhibitorer og som 5-HT2c-receptorligander
NO20003431D0 (no) Nye metalloproteaseinhibitorer, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
DK272684D0 (da) Tetrahydro-beta-carbolin-derivater og fremgangsmaade til fremstilling deraf